08:26 AM EDT, 07/01/2024 (MT Newswires) -- Grifols ( GRFS ) said Monday its Biotest subsidiary forecasts about $1 billion in revenue over the next seven years from US sales of its intravenous immunoglobulin Yimmugo, after recent US Food and Drug Administration approval as a treatment for primary antibody deficiency syndromes.

The drug will launch in Q1 in the US.

Yimmugo has been approved in Europe since late 2022. the company said.

Price: 6.29, Change: -0.02, Percent Change: -0.27